{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:33:42Z","timestamp":1784810022360,"version":"3.55.0"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"42","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Environ Sci Pollut Res"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s11356-021-16096-3","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T13:05:37Z","timestamp":1631451937000},"page":"59570-59593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis"],"prefix":"10.1007","volume":"28","author":[{"given":"Partha","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehedi","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipta","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carla","family":"dos Santos Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakil Ahmed","family":"Polash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabana","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Ferdous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Abu","family":"Kaium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MD. Hasanur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardin Kamal","family":"Jeet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Papadakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khairul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-7840","authenticated-orcid":false,"given":"Md. Sahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"16096_CR1","doi-asserted-by":"crossref","unstructured":"Agostini ML, Andres EL, Sims AC, et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9:","DOI":"10.1128\/mBio.00221-18"},{"key":"16096_CR2","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/jmv.25964","volume":"92","author":"R Alattar","year":"2020","unstructured":"Alattar R, Ibrahim TB, Shaar SH et al (2020) Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol 92:2042\u20132049","journal-title":"J Med Virol"},{"key":"16096_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT, Scott LJ (2018) Baricitinib: a review in rheumatoid arthritis. Drugs 78:761\u2013772","journal-title":"Drugs"},{"key":"16096_CR4","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","volume":"34","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA (2020) Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 34:101615. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101615","journal-title":"Travel Med Infect Dis"},{"key":"16096_CR5","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand K, Ziebuhr J, Wadhwani P et al (2003) Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300:1763\u20131767. https:\/\/doi.org\/10.1126\/science.1085658","journal-title":"Science"},{"key":"16096_CR6","doi-asserted-by":"publisher","first-page":"e039730","DOI":"10.1136\/bmjopen-2020-039730","volume":"10","author":"M Arab-Zozani","year":"2020","unstructured":"Arab-Zozani M, Hassanipour S, Ghoddoosi-Nejad D (2020) Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. BMJ Open 10:e039730","journal-title":"BMJ Open"},{"key":"16096_CR7","doi-asserted-by":"publisher","unstructured":"Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA (2020) Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathog Basel Switz 9. https:\/\/doi.org\/10.3390\/pathogens9030186","DOI":"10.3390\/pathogens9030186"},{"key":"16096_CR8","first-page":"1","volume":"476","author":"P Asrani","year":"2020","unstructured":"Asrani P, Hassan MI (2020) SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions. Mol Cell Biochem 476:1\u201313","journal-title":"Mol Cell Biochem"},{"key":"16096_CR9","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/all.14364","volume":"75","author":"AK Azkur","year":"2020","unstructured":"Azkur AK, Akdis M, Azkur D, Sokolowska M, Veen W, Br\u00fcggen MC, O\u2019Mahony L, Gao Y, Nadeau K, Akdis CA (2020) Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 75:1564\u20131581. https:\/\/doi.org\/10.1111\/all.14364","journal-title":"Allergy"},{"key":"16096_CR10","doi-asserted-by":"publisher","first-page":"e0131412","DOI":"10.1371\/journal.pone.0131412","volume":"10","author":"T Azuma","year":"2015","unstructured":"Azuma T, Ishiuchi H, Inoyama T, Teranishi Y, Yamaoka M, Sato T, Yamashita N, Tanaka H, Mino Y (2015) Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan. PLoS One 10:e0131412. https:\/\/doi.org\/10.1371\/journal.pone.0131412","journal-title":"PLoS One"},{"key":"16096_CR11","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1021\/jm0002679","volume":"43","author":"YS Babu","year":"2000","unstructured":"Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, el-Kattan Y, Lin TH, Hutchison TL, Elliott AJ, Parker CD, Ananth SL, Horn LSL, Laver GW, Montgomery JA (2000) BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43:3482\u20133486","journal-title":"J Med Chem"},{"key":"16096_CR12","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jama.2020.2565","volume":"323","author":"Y Bai","year":"2020","unstructured":"Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M (2020) Presumed asymptomatic carrier transmission of COVID-19. JAMA 323:1406\u20131407. https:\/\/doi.org\/10.1001\/jama.2020.2565","journal-title":"JAMA"},{"key":"16096_CR13","doi-asserted-by":"publisher","first-page":"152956","DOI":"10.1016\/j.phymed.2019.152956","volume":"62","author":"C Bailly","year":"2019","unstructured":"Bailly C (2019) Cepharanthine: An update of its mode of action, pharmacological properties and medical applications. Phytomedicine 62:152956","journal-title":"Phytomedicine"},{"key":"16096_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR et al (2020) Remdesivir for the treatment of Covid-19. N Engl J Med 383:1813\u20131826","journal-title":"N Engl J Med"},{"key":"16096_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2020.1787","volume":"5","author":"F Bessi\u00e8re","year":"2020","unstructured":"Bessi\u00e8re F, Roccia H, Delini\u00e8re A, Charri\u00e8re R, Chevalier P, Argaud L, Cour M (2020) Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol 5:1067\u20131069","journal-title":"JAMA Cardiol"},{"key":"16096_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.antiviral.2013.08.008","volume":"100","author":"J Blaising","year":"2013","unstructured":"Blaising J, L\u00e9vy PL, Polyak SJ, Stanifer M, Boulant S, P\u00e9cheur EI (2013) Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antivir Res 100:215\u2013219. https:\/\/doi.org\/10.1016\/j.antiviral.2013.08.008","journal-title":"Antivir Res"},{"key":"16096_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"J Blaising","year":"2014","unstructured":"Blaising J, Polyak SJ, P\u00e9cheur E-I (2014) Arbidol as a broad-spectrum antiviral: an update. Antivir Res 107:84\u201394","journal-title":"Antivir Res"},{"key":"16096_CR18","doi-asserted-by":"publisher","first-page":"106119","DOI":"10.1016\/j.ijantimicag.2020.106119","volume":"56","author":"HLB Braz","year":"2020","unstructured":"Braz HLB, Silveira JA d M, Marinho AD et al (2020) In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Int J Antimicrob Agents 56:106119. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106119","journal-title":"Int J Antimicrob Agents"},{"key":"16096_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5414\/CPP38387","volume":"38","author":"J Broekhuysen","year":"2000","unstructured":"Broekhuysen J, Stockis A, Lins RL, Graeve JD, Rossignol JF (2000) Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 38:387\u2013394","journal-title":"Int J Clin Pharmacol Ther"},{"key":"16096_CR20","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1172\/JCI141772","volume":"130","author":"V Bronte","year":"2020","unstructured":"Bronte V, Ugel S, Tinazzi E, Vella A, de Sanctis F, Can\u00e8 S, Batani V, Trovato R, Fiore A, Petrova V, Hofer F, Barouni RM, Musiu C, Caligola S, Pinton L, Torroni L, Polati E, Donadello K, Friso S et al (2020) Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest 130:6409\u20136416. https:\/\/doi.org\/10.1172\/JCI141772","journal-title":"J Clin Invest"},{"key":"16096_CR21","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 6:1192\u20131198","journal-title":"Engineering"},{"key":"16096_CR22","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1128\/AAC.01152-15","volume":"59","author":"C Callebaut","year":"2015","unstructured":"Callebaut C, Stepan G, Tian Y, Miller MD (2015) In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate. Antimicrob Agents Chemother 59:5909\u20135916","journal-title":"Antimicrob Agents Chemother"},{"key":"16096_CR23","first-page":"318","volume":"81","author":"F Cantini","year":"2020","unstructured":"Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D (2020) Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Inf Secur 81:318\u2013356","journal-title":"J Inf Secur"},{"key":"16096_CR24","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C et al (2020a) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787\u20131799. https:\/\/doi.org\/10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"key":"16096_CR25","doi-asserted-by":"publisher","first-page":"101647","DOI":"10.1016\/j.tmaid.2020.101647","volume":"35","author":"Y-C Cao","year":"2020","unstructured":"Cao Y-C, Deng Q-X, Dai S-X (2020b) Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med Infect Dis 35:101647. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101647","journal-title":"Travel Med Infect Dis"},{"key":"16096_CR26","unstructured":"Cascella M, Rajnik M, Cuomo A, et al (2020) Features, evaluation, and treatment of coronavirus. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"16096_CR27","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","volume":"63","author":"TM Chapman","year":"2003","unstructured":"Chapman TM, McGavin JK, Noble S (2003) Tenofovir disoproxil fumarate. Drugs 63:1597\u20131608","journal-title":"Drugs"},{"key":"16096_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17512433.2021.1856655","volume":"14","author":"J Charan","year":"2021","unstructured":"Charan J, Kaur RJ, Bhardwaj P, Haque M, Sharma P, Misra S, Godman B (2021a) Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol 14:95\u2013103","journal-title":"Expert Rev Clin Pharmacol"},{"key":"16096_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17512433.2021.1856655","volume":"14","author":"J Charan","year":"2021","unstructured":"Charan J, Kaur RJ, Bhardwaj P, Haque M, Sharma P, Misra S, Godman B (2021b) Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol 14:95\u2013103","journal-title":"Expert Rev Clin Pharmacol"},{"key":"16096_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/22221751.2020.1732837","volume":"9","author":"W Chen","year":"2020","unstructured":"Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, Li L, He R, Tan Y, Deng X, Gao M, Tang G, Zhao L, Wang J, Fan Q, Wen C, Tong Y, Tang Y, Hu F et al (2020) Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect 9:469\u2013473","journal-title":"Emerg Microbes Infect"},{"key":"16096_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s15010-020-01476-7","volume":"48","author":"A Cingolani","year":"2020","unstructured":"Cingolani A, Tummolo AM, Montemurro G, Gremese E, Larosa L, Cipriani MC, Pasciuto G, Liperoti R, Murri R, Pirronti T, Cauda R, Fantoni M, for COVID 2 Columbus Working Group, Bellieni A, Brandi V, Calabrese A, Calvello MR, Ciccullo A, Cingolani A et al (2020) Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection 48:767\u2013771","journal-title":"Infection"},{"key":"16096_CR32","first-page":"1552","volume":"31","author":"GC Clososki","year":"2020","unstructured":"Clososki GC, Soldi RA, da Silva RM et al (2020) Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2. J Braz Chem Soc 31:1552\u20131556","journal-title":"J Braz Chem Soc"},{"key":"16096_CR33","doi-asserted-by":"publisher","first-page":"105923","DOI":"10.1016\/j.ijantimicag.2020.105923","volume":"55","author":"P Colson","year":"2020","unstructured":"Colson P, Rolain J-M, Raoult D (2020) Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 55:105923","journal-title":"Int J Antimicrob Agents"},{"key":"16096_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51:496\u2013505","journal-title":"Clin Infect Dis"},{"key":"16096_CR35","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","volume":"27","author":"M Costanzo","year":"2020","unstructured":"Costanzo M, De Giglio MA, Roviello GN (2020) SARS-CoV-2: recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem 27:4536\u20134541","journal-title":"Curr Med Chem"},{"key":"16096_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/00325481.2017.1285677","volume":"129","author":"CL Cramer","year":"2017","unstructured":"Cramer CL, Patterson A, Alchakaki A, Soubani AO (2017) Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgrad Med 129:493\u2013499","journal-title":"Postgrad Med"},{"key":"16096_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/cpt.1857","volume":"108","author":"B Damle","year":"2020","unstructured":"Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B (2020) Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther 108:201\u2013211","journal-title":"Clin Pharmacol Ther"},{"key":"16096_CR38","doi-asserted-by":"publisher","first-page":"108019","DOI":"10.1016\/j.heares.2020.108019","volume":"395","author":"SN Davis","year":"2020","unstructured":"Davis SN, Wu P, Camci ED, Simon JA, Rubel EW, Raible DW (2020) Chloroquine kills hair cells in zebrafish lateral line and murine cochlear cultures: implications for ototoxicity. Hear Res 395:108019. https:\/\/doi.org\/10.1016\/j.heares.2020.108019","journal-title":"Hear Res"},{"key":"16096_CR39","first-page":"81","volume":"69","author":"E De Clercq","year":"2007","unstructured":"De Clercq E (2007) Anti-HIV drugs. Verh-K Acad Voor Geneeskd Van Belg 69:81\u2013104","journal-title":"Verh-K Acad Voor Geneeskd Van Belg"},{"key":"16096_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1099\/jgv.0.000671","volume":"98","author":"WM de Souza","year":"2017","unstructured":"de Souza WM, Romeiro MF, Fumagalli MJ et al (2017) Chapparvoviruses occur in at least three vertebrate classes and have a broad biogeographic distribution. J Gen Virol 98:225\u2013229","journal-title":"J Gen Virol"},{"key":"16096_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.7326\/M20-3689","volume":"173","author":"J Del Amo","year":"2020","unstructured":"Del Amo J, Polo R, Moreno S et al (2020) Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med 173:536\u2013541","journal-title":"Ann Intern Med"},{"key":"16096_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-020-03078-z","volume":"24","author":"K Doi","year":"2020","unstructured":"Doi K, Ikeda M, Hayase N et al (2020) Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care 24:1\u20134","journal-title":"Crit Care"},{"key":"16096_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 14:58\u201360. https:\/\/doi.org\/10.5582\/ddt.2020.01012","journal-title":"Drug Discov Ther"},{"key":"16096_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen Y-C, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:88\u201395","journal-title":"Ann Rheum Dis"},{"key":"16096_CR45","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2166\/wst.2010.002","volume":"61","author":"JB Ellis","year":"2010","unstructured":"Ellis JB (2010) Antiviral pandemic risk assessment for urban receiving waters. Water Sci Technol J Int Assoc Water Pollut Res 61:879\u2013884. https:\/\/doi.org\/10.2166\/wst.2010.002","journal-title":"Water Sci Technol J Int Assoc Water Pollut Res"},{"key":"16096_CR46","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10753-013-9744-6","volume":"37","author":"Z Ershun","year":"2014","unstructured":"Ershun Z, Yunhe F, Zhengkai W, Yongguo C, Naisheng Z, Zhengtao Y (2014) Cepharanthine attenuates lipopolysaccharide-induced mice mastitis by suppressing the NF-\u03baB signaling pathway. Inflammation 37:331\u2013337","journal-title":"Inflammation"},{"key":"16096_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1261\/rna.076232.120","volume":"26","author":"MN Esbin","year":"2020","unstructured":"Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R (2020) Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA N Y N 26:771\u2013783. https:\/\/doi.org\/10.1261\/rna.076232.120","journal-title":"RNA N Y N"},{"key":"16096_CR48","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","volume":"133","author":"H-H Fan","year":"2020","unstructured":"Fan H-H, Wang L-Q, Liu W-L, An XP, Liu ZD, He XQ, Song LH, Tong YG (2020) Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J 133:1051\u20131056. https:\/\/doi.org\/10.1097\/CM9.0000000000000797","journal-title":"Chin Med J"},{"key":"16096_CR49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1089\/jir.2020.0105","volume":"40","author":"U Fatima","year":"2020","unstructured":"Fatima U, Rizvi SSA, Fatima S, Hassan MI (2020) Impact of hydroxychloroquine\/chloroquine in COVID-19 therapy: two sides of the coin. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 40:469\u2013471. https:\/\/doi.org\/10.1089\/jir.2020.0105","journal-title":"J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res"},{"key":"16096_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol Clifton NJ 1282:1\u201323. https:\/\/doi.org\/10.1007\/978-1-4939-2438-7_1","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"16096_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-27224-4","volume":"8","author":"SL Fink","year":"2018","unstructured":"Fink SL, Vojtech L, Wagoner J et al (2018) The antiviral drug arbidol inhibits Zika virus. Sci Rep 8:1\u20139","journal-title":"Sci Rep"},{"key":"16096_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/vaccines4030023","volume":"4","author":"SB Fleming","year":"2016","unstructured":"Fleming SB (2016) Viral inhibition of the IFN-induced JAK\/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists. Vaccines 4:23","journal-title":"Vaccines"},{"key":"16096_CR53","unstructured":"Food, Administration D (2020a) Emergency use authorization for remdesivir"},{"key":"16096_CR54","unstructured":"Food US, Administration D (2020b) Fact sheet for patients and parent\/caregivers Emergency Use Authorization (EUA) of remdesivir for coronavirus disease 2019 (COVID-19)"},{"key":"16096_CR55","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (2013a) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res 100:446\u2013454","journal-title":"Antivir Res"},{"key":"16096_CR56","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (2013b) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res 100:446\u2013454","journal-title":"Antivir Res"},{"key":"16096_CR57","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honor\u00e9 S, Colson P, Chabri\u00e8re E, la Scola B, Rolain JM, Brouqui P, Raoult D (2020a) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56:105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","journal-title":"Int J Antimicrob Agents"},{"key":"16096_CR58","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honor\u00e9 S, Colson P, Chabri\u00e8re E, la Scola B, Rolain JM, Brouqui P, Raoult D (2020b) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56:105949","journal-title":"Int J Antimicrob Agents"},{"key":"16096_CR59","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1517\/13543784.2012.667072","volume":"21","author":"TN Gengiah","year":"2012","unstructured":"Gengiah TN, Baxter C, Mansoor LE, Kharsany ABM, Abdool Karim SS (2012) A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs 21:695\u2013715","journal-title":"Expert Opin Investig Drugs"},{"key":"16096_CR60","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, G\u00f6tte M (2020) The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 295:4773\u20134779","journal-title":"J Biol Chem"},{"key":"16096_CR61","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.26277","volume":"58","author":"SC Gordon","year":"2013","unstructured":"Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P (2013) Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 58:505\u2013513","journal-title":"Hepatology"},{"key":"16096_CR62","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.scitotenv.2015.09.100","volume":"541","author":"G Grill","year":"2016","unstructured":"Grill G, Khan U, Lehner B, Nicell J, Ariwi J (2016) Risk assessment of down-the-drain chemicals at large spatial scales: Model development and application to contaminants originating from urban areas in the Saint Lawrence River Basin. Sci Total Environ 541:825\u2013838. https:\/\/doi.org\/10.1016\/j.scitotenv.2015.09.100","journal-title":"Sci Total Environ"},{"key":"16096_CR63","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1345\/aph.1C388","volume":"37","author":"SA Grim","year":"2003","unstructured":"Grim SA, Romanelli F (2003) Tenofovir disoproxil fumarate. Ann Pharmacother 37:849\u2013859","journal-title":"Ann Pharmacother"},{"key":"16096_CR64","unstructured":"Group RC (2020) Dexamethasone in hospitalized patients with Covid-19\u2014preliminary report. N Engl J Med"},{"key":"16096_CR65","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","volume":"2","author":"G Guaraldi","year":"2020","unstructured":"Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V, Santoro A, di Gaetano M, Puzzolante C, Carli F, Bedini A, Corradi L, Fantini R, Castaniere I, Tabb\u00ec L et al (2020) Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2:e474\u2013e484","journal-title":"Lancet Rheumatol"},{"key":"16096_CR66","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1053\/j.ajkd.2009.07.012","volume":"54","author":"AM Hall","year":"2009","unstructured":"Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O'Farrell S, Unwin RJ, Williams IG (2009) Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis 54:1034\u20131042","journal-title":"Am J Kidney Dis"},{"key":"16096_CR67","doi-asserted-by":"publisher","unstructured":"Hasana S, Hossain MF, Jalouli M, Kabir MT, Uddin MG, Wahed MII, Behl T, Bin-Jumah MN, Abdel-Daim MM, Aleya L, Uddin MS (2021) Genetic Diversity of SARS-CoV2 and Environmental Settings: Possible Association with Neurological Disorders. Mol Neurobio 58:1917-1931. https:\/\/doi.org\/10.1007\/s12035-020-02239-z","DOI":"10.1007\/s12035-020-02239-z"},{"key":"16096_CR68","doi-asserted-by":"crossref","unstructured":"Hashemian SM, Farhadi T, Velayati AA (2020) A review on favipiravir: the properties, function, and usefulness to treat COVID-19. Expert Rev Anti-Infect Ther:1\u20139","DOI":"10.1080\/14787210.2021.1866545"},{"key":"16096_CR69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/v10040184","volume":"10","author":"J Haviernik","year":"2018","unstructured":"Haviernik J, \u0160tef\u00e1nik M, Fojt\u00edkov\u00e1 M, Kali S, Tordo N, Rudolf I, Hub\u00e1lek Z, Eyer L, Ruzek D (2018) Arbidol (Umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 10:184","journal-title":"Viruses"},{"key":"16096_CR70","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/j.1478-3231.2008.01896.x","volume":"28","author":"WP Hofmann","year":"2008","unstructured":"Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S (2008) Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 28:1332\u20131343","journal-title":"Liver Int"},{"key":"16096_CR71","doi-asserted-by":"publisher","first-page":"106044","DOI":"10.1016\/j.ijantimicag.2020.106044","volume":"56","author":"J Homolak","year":"2020","unstructured":"Homolak J, Kodvanj I (2020) Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents 56:106044","journal-title":"Int J Antimicrob Agents"},{"key":"16096_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2020","unstructured":"Hu B, Guo H, Zhou P, Shi Z-L (2020) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19:141\u2013154. https:\/\/doi.org\/10.1038\/s41579-020-00459-7","journal-title":"Nat Rev Microbiol"},{"key":"16096_CR73","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M et al (2020a) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl 395:497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet Lond Engl"},{"key":"16096_CR74","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/jcm9041131","volume":"9","author":"J Huang","year":"2020","unstructured":"Huang J, Song W, Huang H, Sun Q (2020b) Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19. J Clin Med 9:1131","journal-title":"J Clin Med"},{"key":"16096_CR75","doi-asserted-by":"publisher","unstructured":"Hulseberg CE, F\u00e9n\u00e9ant L, Wijs KMS et al (2019) Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol 93. https:\/\/doi.org\/10.1128\/JVI.02185-18","DOI":"10.1128\/JVI.02185-18"},{"key":"16096_CR76","doi-asserted-by":"publisher","unstructured":"Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G (2020) Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 12. https:\/\/doi.org\/10.3390\/v12040372","DOI":"10.3390\/v12040372"},{"key":"16096_CR77","doi-asserted-by":"publisher","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","volume":"8","author":"Z Jin","year":"2013","unstructured":"Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013) The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347","journal-title":"PLoS One"},{"key":"16096_CR78","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0045-6535(01)00139-4","volume":"46","author":"PK Jjemba","year":"2002","unstructured":"Jjemba PK (2002) The effect of chloroquine, quinacrine, and metronidazole on both soybean plants and soil microbiota. Chemosphere 46:1019\u20131025","journal-title":"Chemosphere"},{"key":"16096_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2648","volume-title":"Dexamethasone in the management of covid-19","author":"RM Johnson","year":"2020","unstructured":"Johnson RM, Vinetz JM (2020) Dexamethasone in the management of covid-19. British Medical Journal Publishing Group"},{"key":"16096_CR80","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","volume":"40","author":"SC Jorgensen","year":"2020","unstructured":"Jorgensen SC, Tse CL, Burry L, Dresser LD (2020) Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacother J Hum Pharmacol Drug Ther 40:843\u2013856","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"16096_CR81","doi-asserted-by":"publisher","first-page":"570927","DOI":"10.3389\/fimmu.2020.570927","volume":"11","author":"K Khalaf","year":"2020","unstructured":"Khalaf K, Papp N, Chou JT-T, Hana D, Mackiewicz A, Kaczmarek M (2020) SARS-CoV-2: pathogenesis, and advancements in diagnostics and treatment. Front Immunol 11:570927. https:\/\/doi.org\/10.3389\/fimmu.2020.570927","journal-title":"Front Immunol"},{"key":"16096_CR82","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/biom9110696","volume":"9","author":"DE Kim","year":"2019","unstructured":"Kim DE, Min JS, Jang MS, Lee J, Shin Y, Park C, Song J, Kim H, Kim S, Jin YH, Kwon S (2019) Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules 9:696","journal-title":"Biomolecules"},{"key":"16096_CR83","doi-asserted-by":"publisher","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","volume":"55","author":"W-C Ko","year":"2020","unstructured":"Ko W-C, Rolain J-M, Lee N-Y, Chen PL, Huang CT, Lee PI, Hsueh PR (2020) Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 55:105933","journal-title":"Int J Antimicrob Agents"},{"key":"16096_CR84","doi-asserted-by":"publisher","first-page":"100123","DOI":"10.1016\/j.osnem.2021.100123","volume":"22","author":"NL Kolluri","year":"2021","unstructured":"Kolluri NL, Murthy D (2021) CoVerifi: A COVID-19 news verification system. Online Soc Netw Media 22:100123. https:\/\/doi.org\/10.1016\/j.osnem.2021.100123","journal-title":"Online Soc Netw Media"},{"key":"16096_CR85","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1068-607X(02)00112-9","volume":"9","author":"CJ Kremer","year":"2002","unstructured":"Kremer CJ (2002) Azithromycin\u2014a new macrolide. Prim Care Update ObGyns 9:174\u2013175","journal-title":"Prim Care Update ObGyns"},{"key":"16096_CR86","doi-asserted-by":"publisher","first-page":"40431","DOI":"10.1007\/s11356-020-12200-1","volume":"28","author":"R Kumar","year":"2021","unstructured":"Kumar R, Sharma A, Srivastava JK, Siddiqui MH, Uddin MS, Aleya L (2021) Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. Environ Sci Pollut Res Int 28:40431\u201340444. https:\/\/doi.org\/10.1007\/s11356-020-12200-1","journal-title":"Environ Sci Pollut Res Int"},{"key":"16096_CR87","doi-asserted-by":"publisher","unstructured":"Kumar R, Srivastava JK, Singh R, Siddiqui MH, Mansouri RA, Abdulhakim JA, Bin-Jumah MN, Alkahtani S, Abdel-Daim MM, Uddin MS (2020) Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies Supportive Care and Probable Vaccines. Frontiers Pharmacol 11:582025. https:\/\/doi.org\/10.3389\/fphar.2020.582025\u00a0","DOI":"10.3389\/fphar.2020.582025"},{"key":"16096_CR88","doi-asserted-by":"publisher","first-page":"145740","DOI":"10.1016\/j.scitotenv.2021.145740","volume":"776","author":"K Kuroda","year":"2021","unstructured":"Kuroda K, Li C, Dhangar K, Kumar M (2021) Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters. Sci Total Environ 776:145740","journal-title":"Sci Total Environ"},{"key":"16096_CR89","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41565-020-0752-z","volume":"15","author":"T Lammers","year":"2020","unstructured":"Lammers T, Sofias AM, van der Meel R, Schiffelers R, Storm G, Tacke F, Koschmieder S, Br\u00fcmmendorf TH, Kiessling F, Metselaar JM (2020) Dexamethasone nanomedicines for COVID-19. Nat Nanotechnol 15:622\u2013624","journal-title":"Nat Nanotechnol"},{"key":"16096_CR90","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/S2665-9913(20)30276-9","volume":"2","author":"JCE Lane","year":"2020","unstructured":"Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall S, Dymshyts D, Fernandez-Bertolin S, Fi\u0161ter K et al (2020) Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol 2:e698\u2013e711. https:\/\/doi.org\/10.1016\/S2665-9913(20)30276-9","journal-title":"Lancet Rheumatol"},{"key":"16096_CR91","doi-asserted-by":"publisher","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","volume":"42","author":"V Law","year":"2014","unstructured":"Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS (2014) DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42:D1091\u2013D1097","journal-title":"Nucleic Acids Res"},{"key":"16096_CR92","first-page":"52","volume":"90","author":"S Leecharoen","year":"2007","unstructured":"Leecharoen S, Wangkaew S, Louthrenoo W (2007) Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J-Med Assoc Thail 90:52","journal-title":"J-Med Assoc Thail"},{"key":"16096_CR93","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.scitotenv.2011.11.004","volume":"414","author":"H Leknes","year":"2012","unstructured":"Leknes H, Sturtzel IE, Dye C (2012) Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic. Sci Total Environ 414:632\u2013638. https:\/\/doi.org\/10.1016\/j.scitotenv.2011.11.004","journal-title":"Sci Total Environ"},{"key":"16096_CR94","doi-asserted-by":"crossref","unstructured":"Li C, Zu S, Deng Y-Q, et al (2019) Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses Antimicrob Agents Chemother 63:","DOI":"10.1128\/AAC.00394-19"},{"key":"16096_CR95","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijantimicag.2017.09.001","volume":"51","author":"M Li","year":"2018","unstructured":"Li M, Liu Y, Wei F, Shen MX, Zhong Y, Li S, Chen LJ, Ma N, Liu BY, Mao YD, Li N, Hou W, Xiong HR, Yang ZQ (2018) Antiviral activity of Arbidol hydrochloride against herpes simplex virus I in vitro and in vivo. Int J Antimicrob Agents 51:98\u2013106","journal-title":"Int J Antimicrob Agents"},{"key":"16096_CR96","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.medj.2020.04.001","volume":"1","author":"Y Li","year":"2020","unstructured":"Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, Mo X, Wang J, Wang Y, Peng P, Chen X, Hong W, Xiao G, Liu J, Zhang L, Hu F, Li F, Zhang F, Deng X, Li L (2020) Efficacy and safety of lopinavir\/ritonavir or Arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial. Med 1:105\u2013113","journal-title":"Med"},{"key":"16096_CR97","doi-asserted-by":"crossref","unstructured":"Lighter J, Raabe V (2020) Azithromycin should not be used to treat COVID-19. In: Open forum infectious diseases. Oxford University Press US, p ofaa207","DOI":"10.1093\/ofid\/ofaa207"},{"key":"16096_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/37.suppl_C.1","volume":"37","author":"H Lode","year":"1996","unstructured":"Lode H, Borner K, Koeppe P, Schaberg T (1996) Azithromycin\u2014review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 37:1\u20138","journal-title":"J Antimicrob Chemother"},{"key":"16096_CR99","volume-title":"Review of the 1st Watch List under the Water Framework Directive and recommendations for the 2nd Watch List","author":"R Loos","year":"2018","unstructured":"Loos R, Marinov D, Sanseverino I et al (2018) Review of the 1st Watch List under the Water Framework Directive and recommendations for the 2nd Watch List. Luxemb Publ Off Eur Union"},{"key":"16096_CR100","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu H (2020a) Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 14:69\u201371","journal-title":"Biosci Trends"},{"key":"16096_CR101","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu H (2020b) Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 14:69\u201371. https:\/\/doi.org\/10.5582\/bst.2020.01020","journal-title":"Biosci Trends"},{"key":"16096_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43141-020-00055-5","volume":"18","author":"DB Mahmoud","year":"2020","unstructured":"Mahmoud DB, Shitu Z, Mostafa A (2020) Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? J Genet Eng Biotechnol 18:1\u201310","journal-title":"J Genet Eng Biotechnol"},{"key":"16096_CR103","first-page":"3","volume":"42","author":"YA Malik","year":"2020","unstructured":"Malik YA (2020) Properties of Coronavirus and SARS-CoV-2. Malays J Pathol 42:3\u201311","journal-title":"Malays J Pathol"},{"key":"16096_CR104","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.cgh.2014.11.021","volume":"13","author":"V Mallet","year":"2015","unstructured":"Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S (2015) Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin Gastroenterol Hepatol 13:1181\u20131188","journal-title":"Clin Gastroenterol Hepatol"},{"key":"16096_CR105","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1592\/phco.21.17.1352.34419","volume":"21","author":"EM Mangum","year":"2001","unstructured":"Mangum EM, Graham KK (2001) Lopinavir-ritonavir: a new protease inhibitor. Pharmacother J Hum Pharmacol Drug Ther 21:1352\u20131363","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"16096_CR106","doi-asserted-by":"publisher","first-page":"28698","DOI":"10.1038\/srep28698","volume":"6","author":"M Menzel","year":"2016","unstructured":"Menzel M, Akbarshahi H, Bjermer L, Uller L (2016) Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep 6:28698. https:\/\/doi.org\/10.1038\/srep28698","journal-title":"Sci Rep"},{"key":"16096_CR107","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","volume":"5","author":"NJ Mercuro","year":"2020","unstructured":"Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS (2020) Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 5:1036\u20131041","journal-title":"JAMA Cardiol"},{"key":"16096_CR108","doi-asserted-by":"publisher","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","volume":"35","author":"M Million","year":"2020","unstructured":"Million M, Lagier J-C, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C et al (2020) Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 35:101738. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101738","journal-title":"Travel Med Infect Dis"},{"key":"16096_CR109","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1016\/j.cgh.2020.07.050","volume":"18","author":"F Montastruc","year":"2020","unstructured":"Montastruc F, Thuriot S, Durrieu G (2020) Hepatic disorders with the use of remdesivir for coronavirus 2019. Clin Gastroenterol Hepatol 18:2835\u20132836","journal-title":"Clin Gastroenterol Hepatol"},{"key":"16096_CR110","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jmii.2020.03.022","volume":"10","author":"L Mousavizadeh","year":"2020","unstructured":"Mousavizadeh L, Ghasemi S (2020) Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi 10:159\u2013163. https:\/\/doi.org\/10.1016\/j.jmii.2020.03.022","journal-title":"J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi"},{"key":"16096_CR111","doi-asserted-by":"crossref","unstructured":"Mubagwa K (2020) Chloroquine cardiac effects and toxicity. A short update Int J Antimicrob Agents 106057","DOI":"10.1016\/j.ijantimicag.2020.106057"},{"key":"16096_CR112","doi-asserted-by":"publisher","first-page":"992","DOI":"10.17179\/excli2020-2554","volume":"19","author":"A Nabil","year":"2020","unstructured":"Nabil A, Uto K, Elshemy MM et al (2020) Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: an updated review until June 2020. EXCLI J 19:992\u20131016. https:\/\/doi.org\/10.17179\/excli2020-2554","journal-title":"EXCLI J"},{"key":"16096_CR113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0005-2736(82)90226-7","volume":"691","author":"S Nagatsuka","year":"1982","unstructured":"Nagatsuka S, Nakazawa T (1982) Effects of membrane-stabilizing agents, cholesterol and cepharanthin, on radiation-induced lipid peroxidation and permeability in liposomes. Biochim Biophys Acta BBA-Biomembr 691:171\u2013177","journal-title":"Biochim Biophys Acta BBA-Biomembr"},{"key":"16096_CR114","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/bs.aivir.2016.08.001","volume":"96","author":"K Nakagawa","year":"2016","unstructured":"Nakagawa K, Lokugamage KG, Makino S (2016) Viral and cellular mRNA translation in coronavirus-infected cells. Adv Virus Res 96:165\u2013192","journal-title":"Adv Virus Res"},{"key":"16096_CR115","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1128\/AAC.01023-06","volume":"51","author":"H Noedl","year":"2007","unstructured":"Noedl H, Krudsood S, Leowattana W, Tangpukdee N, Thanachartwet W, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Yingyuen K, Sriwichai S, Ohrt C, Knirsch C (2007) In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother 51:651\u2013656","journal-title":"Antimicrob Agents Chemother"},{"key":"16096_CR116","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2141.1983.tb02849.x","volume":"55","author":"ST Ohnishi","year":"1983","unstructured":"Ohnishi ST (1983) Inhibition of the in vitro formation of irreversibly sickled cells by cepharanthine. Br J Haematol 55:665\u2013671","journal-title":"Br J Haematol"},{"key":"16096_CR117","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1089\/aid.1998.14.1239","volume":"14","author":"M OKAMOTO","year":"1998","unstructured":"OKAMOTO M, ONO M, BABA M (1998) Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res Hum Retrovir 14:1239\u20131245","journal-title":"AIDS Res Hum Retrovir"},{"key":"16096_CR118","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2165\/00003495-200666090-00012","volume":"66","author":"V Oldfield","year":"2006","unstructured":"Oldfield V, Plosker GL (2006) Lopinavir\/ritonavir. Drugs 66:1275\u20131299","journal-title":"Drugs"},{"key":"16096_CR119","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tiv.2016.03.010","volume":"34","author":"KR Paudel","year":"2016","unstructured":"Paudel KR, Karki R, Kim D-W (2016) Cepharanthine inhibits in vitro VSMC proliferation and migration and vascular inflammatory responses mediated by RAW264. 7. Toxicol in Vitro 34:16\u201325","journal-title":"Toxicol in Vitro"},{"key":"16096_CR120","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","volume":"6","author":"V Pilkington","year":"2020","unstructured":"Pilkington V, Pepperrell T, Hill A (2020) A review of the safety of favipiravir\u2013a potential treatment in the COVID-19 pandemic? J Virus Erad 6:45\u201351","journal-title":"J Virus Erad"},{"key":"16096_CR121","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/jclinpath-2020-206658","volume":"73","author":"TS Pillay","year":"2020","unstructured":"Pillay TS (2020) Gene of the month: the 2019-nCoV\/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol 73:366\u2013369. https:\/\/doi.org\/10.1136\/jclinpath-2020-206658","journal-title":"J Clin Pathol"},{"key":"16096_CR122","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","volume":"38","author":"D Plantone","year":"2018","unstructured":"Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 38:653\u2013671","journal-title":"Clin Drug Investig"},{"key":"16096_CR123","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1473-3099(20)30296-6","volume":"20","author":"N Principi","year":"2020","unstructured":"Principi N, Esposito S (2020) Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis 20:1118. https:\/\/doi.org\/10.1016\/S1473-3099(20)30296-6","journal-title":"Lancet Infect Dis"},{"key":"16096_CR124","doi-asserted-by":"publisher","first-page":"107940","DOI":"10.1016\/j.celrep.2020.107940","volume":"32","author":"AJ Pruijssers","year":"2020","unstructured":"Pruijssers AJ, George AS, Sch\u00e4fer A, Leist SR, Gralinksi LE, Dinnon KH III, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, du Pont V, Pitts J et al (2020) Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep 32:107940","journal-title":"Cell Rep"},{"key":"16096_CR125","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1001\/jamainternmed.2020.2904","volume":"180","author":"K Pundi","year":"2020","unstructured":"Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP (2020) Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials. gov. JAMA Intern Med 180:1398\u20131400","journal-title":"JAMA Intern Med"},{"key":"16096_CR126","doi-asserted-by":"publisher","first-page":"109808","DOI":"10.1016\/j.envres.2020.109808","volume":"188","author":"M Race","year":"2020","unstructured":"Race M, Ferraro A, Galdiero E, Guida M, N\u00fa\u00f1ez-Delgado A, Pirozzi F, Siciliano A, Fabbricino M (2020) Current emerging SARS-CoV-2 pandemic: potential direct\/indirect negative impacts of virus persistence and related therapeutic drugs on the aquatic compartments. Environ Res 188:109808","journal-title":"Environ Res"},{"key":"16096_CR127","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.toxrep.2017.11.006","volume":"5","author":"M Ramesh","year":"2018","unstructured":"Ramesh M, Anitha S, Poopal RK, Shobana C (2018) Evaluation of acute and sublethal effects of chloroquine (C18H26CIN3) on certain enzymological and histopathological biomarker responses of a freshwater fish Cyprinus carpio. Toxicol Rep 5:18\u201327","journal-title":"Toxicol Rep"},{"key":"16096_CR128","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ (2016) Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antivir Res 125:63\u201370","journal-title":"Antivir Res"},{"key":"16096_CR129","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/17476348.2020.1778470","volume":"14","author":"C Robba","year":"2020","unstructured":"Robba C, Battaglini D, Pelosi P, Rocco PRM (2020) Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert Rev Respir Med 14:865\u2013868. https:\/\/doi.org\/10.1080\/17476348.2020.1778470","journal-title":"Expert Rev Respir Med"},{"key":"16096_CR130","doi-asserted-by":"publisher","first-page":"105733","DOI":"10.1016\/j.envint.2020.105733","volume":"140","author":"S Rodriguez-Mozaz","year":"2020","unstructured":"Rodriguez-Mozaz S, Vaz-Moreira I, Varela Della Giustina S, Llorca M, Barcel\u00f3 D, Schubert S, Berendonk TU, Michael-Kordatou I, Fatta-Kassinos D, Martinez JL, Elpers C, Henriques I, Jaeger T, Schwartz T, Paulshus E, O'Sullivan K, P\u00e4rn\u00e4nen KMM, Virta M, Do TT et al (2020) Antibiotic residues in final effluents of European wastewater treatment plants and their impact on the aquatic environment. Environ Int 140:105733. https:\/\/doi.org\/10.1016\/j.envint.2020.105733","journal-title":"Environ Int"},{"key":"16096_CR131","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1734-1140(11)70500-X","volume":"63","author":"M Rogosnitzky","year":"2011","unstructured":"Rogosnitzky M, Danks R (2011a) Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol Rep 63:337\u2013347","journal-title":"Pharmacol Rep"},{"key":"16096_CR132","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1734-1140(11)70500-X","volume":"63","author":"M Rogosnitzky","year":"2011","unstructured":"Rogosnitzky M, Danks R (2011b) Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol Rep 63:337\u2013347","journal-title":"Pharmacol Rep"},{"key":"16096_CR133","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","volume":"109","author":"HA Rothan","year":"2020","unstructured":"Rothan HA, Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109:102433. https:\/\/doi.org\/10.1016\/j.jaut.2020.102433","journal-title":"J Autoimmun"},{"key":"16096_CR134","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","volume":"63","author":"PJ Ruane","year":"2013","unstructured":"Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, S. Rhee M, Fordyce MW, Yale K (2013) Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1\u2013positive adults. JAIDS J Acquir Immune Defic Syndr 63:449\u2013455","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"16096_CR135","doi-asserted-by":"publisher","first-page":"105945","DOI":"10.1016\/j.ijantimicag.2020.105945","volume":"55","author":"Z Sahraei","year":"2020","unstructured":"Sahraei Z, Shabani M, Shokouhi S, Saffaei A (2020) Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents 55:105945","journal-title":"Int J Antimicrob Agents"},{"key":"16096_CR136","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.intimp.2006.09.008","volume":"7","author":"S Sakaguchi","year":"2007","unstructured":"Sakaguchi S, Furusawa S, Wu J, Nagata K (2007) Preventive effects of a biscoclaurine alkaloid, cepharanthine, on endotoxin or tumor necrosis factor-\u03b1-induced septic shock symptoms: involvement of from cell death in L929 cells and nitric oxide production in raw 264.7 cells. Int Immunopharmacol 7:191\u2013197","journal-title":"Int Immunopharmacol"},{"key":"16096_CR137","first-page":"143","volume":"19","author":"SL Seneviratne","year":"2020","unstructured":"Seneviratne SL, Abeysuriya V, De Mel S et al (2020) Favipiravir in COVID-19. Int J Progress Sci Technol 19:143\u2013145","journal-title":"Int J Progress Sci Technol"},{"key":"16096_CR138","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1570163814666170727130003","volume":"15","author":"A Shakya","year":"2018","unstructured":"Shakya A, Bhat HR, Ghosh SK (2018) Update on nitazoxanide: a multifunctional chemotherapeutic agent. Curr Drug Discov Technol 15:201\u2013213","journal-title":"Curr Drug Discov Technol"},{"key":"16096_CR139","doi-asserted-by":"publisher","first-page":"e108621","DOI":"10.1371\/journal.pone.0108621","volume":"9","author":"AC Singer","year":"2014","unstructured":"Singer AC, J\u00e4rhult JD, Grabic R, Khan GA, Lindberg RH, Fedorova G, Fick J, Bowes MJ, Olsen B, S\u00f6derstr\u00f6m H (2014) Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers. PLoS One 9:e108621. https:\/\/doi.org\/10.1371\/journal.pone.0108621","journal-title":"PLoS One"},{"key":"16096_CR140","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.dsx.2020.05.018","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh A, Singh R, Misra A (2020) Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr Clin Res Rev 14:641\u2013648","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"16096_CR141","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cytogfr.2020.06.012","volume":"54","author":"C Solinas","year":"2020","unstructured":"Solinas C, Perra L, Aiello M, Migliori E, Petrosillo N (2020) A critical evaluation of glucocorticoids in the treatment of severe COVID-19. Cytokine Growth Factor Rev 54:8\u201323","journal-title":"Cytokine Growth Factor Rev"},{"key":"16096_CR142","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, Arribas L\u00f3pez JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO et al (2020) Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324:1048\u20131057. https:\/\/doi.org\/10.1001\/jama.2020.16349","journal-title":"JAMA"},{"key":"16096_CR143","doi-asserted-by":"publisher","first-page":"8824","DOI":"10.1128\/JVI.78.16.8824-8834.2004","volume":"78","author":"JR St-Jean","year":"2004","unstructured":"St-Jean JR, Jacomy H, Desforges M et al (2004) Human respiratory coronavirus OC43: genetic stability and neuroinvasion. J Virol 78:8824\u20138834","journal-title":"J Virol"},{"key":"16096_CR144","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 en la inflamaci\u00f3n, la inmunidad, y la enfermedad. Cold Spring Harb Perspect Biol 6:a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"16096_CR145","doi-asserted-by":"publisher","first-page":"146257","DOI":"10.1016\/j.scitotenv.2021.146257","volume":"778","author":"JV Tarazona","year":"2021","unstructured":"Tarazona JV, Mart\u00ednez M, Mart\u00ednez M-A, Anad\u00f3n A (2021) Environmental impact assessment of COVID-19 therapeutic solutions. A prospective analysis. Sci Total Environ 778:146257","journal-title":"Sci Total Environ"},{"key":"16096_CR146","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, Issa M, Salinas CA, Saifan C, Zhang X, Cardoso A, Gonz\u00e1lez-Gay MA, Takeuchi T (2019) Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheum 71:1042\u20131055","journal-title":"Arthritis Rheum"},{"key":"16096_CR147","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","volume":"9","author":"R Taylor","year":"2016","unstructured":"Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J, Dobo S, Rose A, el-Kattan Y, Taubenheim B, Babu Y, Sheridan WP (2016) BCX4430\u2013a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health 9:220\u2013226","journal-title":"J Infect Public Health"},{"key":"16096_CR148","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/v11040326","volume":"11","author":"EP Tchesnokov","year":"2019","unstructured":"Tchesnokov EP, Feng JY, Porter DP, G\u00f6tte M (2019a) Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11:326. https:\/\/doi.org\/10.3390\/v11040326","journal-title":"Viruses"},{"key":"16096_CR149","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/v11040326","volume":"11","author":"EP Tchesnokov","year":"2019","unstructured":"Tchesnokov EP, Feng JY, Porter DP, G\u00f6tte M (2019b) Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11:326","journal-title":"Viruses"},{"key":"16096_CR150","doi-asserted-by":"publisher","first-page":"e15874","DOI":"10.1371\/journal.pone.0015874","volume":"6","author":"E Teissier","year":"2011","unstructured":"Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, B\u00f6ckmann A, Meier BH, Penin F, P\u00e9cheur EI (2011) Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug Arbidol. PLoS One 6:e15874. https:\/\/doi.org\/10.1371\/journal.pone.0015874","journal-title":"PLoS One"},{"key":"16096_CR151","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1093\/jac\/dkaa239","volume":"75","author":"M Tempestilli","year":"2020","unstructured":"Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni L, Ascoli Bartoli T, Castilletti C, Lalle E, Capobianchi MR, Nicastri E, D\u2019Avolio A, Ippolito G, Agrati C, the COVID 19 INMI Study Group, Abbonizio MA, Agrati C, Albarello F et al (2020) Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75:2977\u20132980","journal-title":"J Antimicrob Chemother"},{"key":"16096_CR152","first-page":"10","volume":"34","author":"TC Theoharides","year":"2020","unstructured":"Theoharides TC, Conti P (2020) Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents 34:10\u201323812","journal-title":"J Biol Regul Homeost Agents"},{"key":"16096_CR153","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/cid\/ciaa879","volume":"72","author":"BK Titanji","year":"2020","unstructured":"Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, O\u2019Shea J, DeSilva K, Chan B, Edwards A, Gavegnano C, Schinazi RF, Marconi VC (2020) Use of baricitinib in patients with moderate and severe COVID-19. Clin Infect Dis Off Publ Infect Dis Soc Am 72:1247\u20131250. https:\/\/doi.org\/10.1093\/cid\/ciaa879","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"16096_CR154","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/jmv.26637","volume":"93","author":"D d A Torres","year":"2021","unstructured":"Torres D d A, Ribeiro L d CB, Riello AP d FL et al (2021) Reinfection of COVID-19 after 3 months with a distinct and more aggressive clinical presentation: case report. J Med Virol 93:1857\u20131859. https:\/\/doi.org\/10.1002\/jmv.26637","journal-title":"J Med Virol"},{"key":"16096_CR155","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","volume":"177","author":"F Touret","year":"2020","unstructured":"Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antivir Res 177:104762","journal-title":"Antivir Res"},{"key":"16096_CR156","doi-asserted-by":"publisher","first-page":"e13476","DOI":"10.1111\/dth.13476","volume":"33","author":"\u00dc T\u00fcrsen","year":"2020","unstructured":"T\u00fcrsen \u00dc, T\u00fcrsen B, Lotti T (2020) Cutaneous s\u0131de-effects of the potential COVID-19 drugs. Dermatol Ther 33:e13476","journal-title":"Dermatol Ther"},{"key":"16096_CR157","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1006\/excr.2002.5613","volume":"281","author":"D Tyteca","year":"2002","unstructured":"Tyteca D, Van Der Smissen P, Mettlen M et al (2002) Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages. Exp Cell Res 281:86\u2013100","journal-title":"Exp Cell Res"},{"key":"16096_CR158","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm1024","volume":"10","author":"L van der Hoek","year":"2004","unstructured":"van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJM, Wolthers KC, Wertheim-van Dillen PME, Kaandorp J, Spaargaren J, Berkhout B (2004) Identification of a new human coronavirus. Nat Med 10:368\u2013373. https:\/\/doi.org\/10.1038\/nm1024","journal-title":"Nat Med"},{"key":"16096_CR159","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jcv.2014.09.016","volume":"61","author":"M Vigan\u00f2","year":"2014","unstructured":"Vigan\u00f2 M, Brocchieri A, Spinetti A, Zaltron S, Mangia G, Facchetti F, Fugazza A, Castelli F, Colombo M, Lampertico P (2014) Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. J Clin Virol 61:600\u2013603","journal-title":"J Clin Virol"},{"key":"16096_CR160","doi-asserted-by":"publisher","unstructured":"Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 181:281, 281\u2013292.e6, 292.e6. https:\/\/doi.org\/10.1016\/j.cell.2020.02.058","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"16096_CR161","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020a) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"16096_CR162","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","volume":"182","author":"Q Wang","year":"2020","unstructured":"Wang Q, Wu J, Wang H, Gao Y, Liu Q, Mu A, Ji W, Yan L, Zhu Y, Zhu C, Fang X, Yang X, Huang Y, Gao H, Liu F, Ge J, Sun Q, Yang X, Xu W et al (2020b) Structural basis for RNA replication by the SARS-CoV-2 Polymerase. Cell 182:417\u2013428.e13. https:\/\/doi.org\/10.1016\/j.cell.2020.05.034","journal-title":"Cell"},{"key":"16096_CR163","first-page":"350","volume":"80","author":"R Wang","year":"2020","unstructured":"Wang R, Zhang X, Irwin DM, Shen Y (2020c) Emergence of SARS-like coronavirus poses new challenge in China. J Inf Secur 80:350\u2013371","journal-title":"J Inf Secur"},{"key":"16096_CR164","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jinf.2020.01.017","volume":"80","author":"R Wang","year":"2020","unstructured":"Wang R, Zhang X, Irwin DM, Shen Y (2020d) Emergence of SARS-like coronavirus poses new challenge in China. J Inf Secur 80:350\u2013371. https:\/\/doi.org\/10.1016\/j.jinf.2020.01.017","journal-title":"J Inf Secur"},{"key":"16096_CR165","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G et al (2020e) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569\u20131578","journal-title":"Lancet"},{"key":"16096_CR166","doi-asserted-by":"crossref","unstructured":"Wang Z, Chen X, Lu Y, et al (2020f) Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends","DOI":"10.5582\/bst.2020.01030"},{"key":"16096_CR167","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.antiviral.2018.05.013","volume":"156","author":"JB Westover","year":"2018","unstructured":"Westover JB, Mathis A, Taylor R, Wandersee L, Bailey KW, Sefing EJ, Hickerson BT, Jung KH, Sheridan WP, Gowen BB (2018) Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antivir Res 156:38\u201345","journal-title":"Antivir Res"},{"key":"16096_CR168","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36:D901\u2013D906","journal-title":"Nucleic Acids Res"},{"key":"16096_CR169","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444\u20131448. https:\/\/doi.org\/10.1126\/science.abb2762","journal-title":"Science"},{"key":"16096_CR170","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1126\/science.abd2321","volume":"369","author":"M Yuan","year":"2020","unstructured":"Yuan M, Liu H, Wu NC, Lee CCD, Zhu X, Zhao F, Huang D, Yu W, Hua Y, Tien H, Rogers TF, Landais E, Sok D, Jardine JG, Burton DR, Wilson IA (2020) Structural basis of a shared antibody response to SARS-CoV-2. Science 369:1119\u20131123. https:\/\/doi.org\/10.1126\/science.abd2321","journal-title":"Science"},{"key":"16096_CR171","first-page":"173","volume":"73","author":"PJ Zed","year":"2020","unstructured":"Zed PJ (2020) Pharmacy Leadership during the COVID-19 Pandemic. Can J Hosp Pharm 73:173\u2013174","journal-title":"Can J Hosp Pharm"},{"key":"16096_CR172","first-page":"493","volume":"118","author":"C Zhang","year":"2005","unstructured":"Zhang C, Wang Y, Liu X, Lu JH, Qian CW, Wan ZY, Yan XG, Zheng HY, Zhang MY, Xiong S, Li JX, Qi SY (2005) Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro. Chin Med J 118:493\u2013496","journal-title":"Chin Med J"},{"key":"16096_CR173","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 368:409\u2013412","journal-title":"Science"},{"key":"16096_CR174","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","volume":"27","author":"D Zhou","year":"2020","unstructured":"Zhou D, Duyvesteyn HME, Chen C-P, Huang CG, Chen TH, Shih SR, Lin YC, Cheng CY, Cheng SH, Huang YC, Lin TY, Ma C, Huo J, Carrique L, Malinauskas T, Ruza RR, Shah PNM, Tan TK, Rijal P et al (2020a) Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol 27:950\u2013958. https:\/\/doi.org\/10.1038\/s41594-020-0480-y","journal-title":"Nat Struct Mol Biol"},{"key":"16096_CR175","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","volume":"291","author":"N Zhou","year":"2016","unstructured":"Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C, Tao L, Zhang H (2016) Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome\/lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 291:9218\u20139232","journal-title":"J Biol Chem"},{"key":"16096_CR176","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020b) Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov 6:14. https:\/\/doi.org\/10.1038\/s41421-020-0153-3","journal-title":"Cell Discov"},{"key":"16096_CR177","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017","journal-title":"N Engl J Med"},{"key":"16096_CR178","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"A Zumla","year":"2016","unstructured":"Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY (2016) Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 15:327\u2013347. https:\/\/doi.org\/10.1038\/nrd.2015.37","journal-title":"Nat Rev Drug Discov"},{"key":"16096_CR179","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.aquatox.2005.07.009","volume":"75","author":"JL Zurita","year":"2005","unstructured":"Zurita JL, Jos \u00c1, del Peso A et al (2005) Ecotoxicological evaluation of the antimalarial drug chloroquine. Aquat Toxicol 75:97\u2013107","journal-title":"Aquat Toxicol"},{"key":"16096_CR180","unstructured":"(2020) WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2D%2D-11-march-2020. Accessed 11 Feb 2021"}],"container-title":["Environmental Science and Pollution Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-021-16096-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11356-021-16096-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-021-16096-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T11:13:11Z","timestamp":1675681991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11356-021-16096-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":180,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["16096"],"URL":"https:\/\/doi.org\/10.1007\/s11356-021-16096-3","relation":{},"ISSN":["0944-1344","1614-7499"],"issn-type":[{"value":"0944-1344","type":"print"},{"value":"1614-7499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,12]]},"assertion":[{"value":"9 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}